380 related articles for article (PubMed ID: 31506007)
21. Review of Medical Management of Primary Biliary Cholangitis.
Rajendiran G; Mankongpaisarnrung C; Olivera-Martinez MA; McCashland TM
S D Med; 2021 Dec; 74(12):562-568. PubMed ID: 35015947
[TBL] [Abstract][Full Text] [Related]
22. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
23. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Rust C; Beuers U
Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
[TBL] [Abstract][Full Text] [Related]
24. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives.
Barba Bernal R; Ferrigno B; Medina Morales E; Castro CM; Goyes D; Trivedi H; Patwardhan VR; Bonder A
Turk J Gastroenterol; 2023 Feb; 34(2):89-100. PubMed ID: 36843300
[TBL] [Abstract][Full Text] [Related]
25. Current and potential treatments for primary biliary cholangitis.
Shah RA; Kowdley KV
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
[TBL] [Abstract][Full Text] [Related]
26. [Autoimmune mediated cholestatic liver diseases].
Mayer LS; Käser R; Böttler T
Dtsch Med Wochenschr; 2020 Mar; 145(5):296-305. PubMed ID: 32120404
[TBL] [Abstract][Full Text] [Related]
27. New therapies target the toxic consequences of cholestatic liver disease.
Jansen PLM
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
[TBL] [Abstract][Full Text] [Related]
28. [Ursodeoxycholic acid: history and clinical implications].
Beuers U; Trampert DC
Ned Tijdschr Geneeskd; 2022 Sep; 166():. PubMed ID: 36300467
[TBL] [Abstract][Full Text] [Related]
29. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
[TBL] [Abstract][Full Text] [Related]
30. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach.
Mousa HS; Carbone M; Malinverno F; Ronca V; Gershwin ME; Invernizzi P
Autoimmun Rev; 2016 Sep; 15(9):870-6. PubMed ID: 27393766
[TBL] [Abstract][Full Text] [Related]
32. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
33. Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies.
Gerussi A; D'Amato D; Cristoferi L; O'Donnell SE; Carbone M; Invernizzi P
Ann Hepatol; 2020; 19(1):5-16. PubMed ID: 31771820
[TBL] [Abstract][Full Text] [Related]
34. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
35. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
Ahn DW
Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
[TBL] [Abstract][Full Text] [Related]
36. The challenges of primary biliary cholangitis: What is new and what needs to be done.
Terziroli Beretta-Piccoli B; Mieli-Vergani G; Vergani D; Vierling JM; Adams D; Alpini G; Banales JM; Beuers U; Björnsson E; Bowlus C; Carbone M; Chazouillères O; Dalekos G; De Gottardi A; Harada K; Hirschfield G; Invernizzi P; Jones D; Krawitt E; Lanzavecchia A; Lian ZX; Ma X; Manns M; Mavilio D; Quigley EM; Sallusto F; Shimoda S; Strazzabosco M; Swain M; Tanaka A; Trauner M; Tsuneyama K; Zigmond E; Gershwin ME
J Autoimmun; 2019 Dec; 105():102328. PubMed ID: 31548157
[TBL] [Abstract][Full Text] [Related]
37. Ursodeoxycholic acid therapy in hepatobiliary disease.
Kowdley KV
Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
[TBL] [Abstract][Full Text] [Related]
38. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
Silveira MG; Lindor KD
Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of cholestatic liver diseases].
Karvonen AL
Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
[No Abstract] [Full Text] [Related]
40. Current pharmacotherapy for cholestatic liver disease.
Carey EJ; Lindor KD
Expert Opin Pharmacother; 2012 Dec; 13(17):2473-84. PubMed ID: 23094715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
